Dr. Schonholz is a psychiatry resident, Mount Sinai Hospital, New York, NY. Dr. Appel is a Professor of Psychiatry and Medical Education, Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Bursztajn is an Associate Professor of Psychiatry and cofounder, Program in Psychiatry and the Law, Beth Israel Deaconess Medical Center Psychiatry, Harvard Medical School, Boston, MA and President, American Unit of the International Chair in Bioethics, Cambridge, MA. Dr. Nair is in private practice, Clinical & Forensic Neuropsychiatry/Brain Injury Medicine, Seal Beach, CA. Dr. MacIntyre is a Health Sciences Clinical Assistant Professor, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA.
1 paper in the library · 3 citations · publishing 2024
Psilocybin shows promise as a treatment for psychiatric illnesses, but its federal illegality in the U.S. complicates access and regulation despite state-level decriminalization efforts. This article reviews current legal regulation, standard of care, right to effective treatment, and the respectable minority doctrine. It discusses ethical issues including provider bias, patient-provider dynamics, informed consent, and equity and access that psychiatrists must consider as psilocybin access expands for research.